Company overview
Basic information
Company name
OncoAlert 360, VšĮ
Company code
306289333
Registered address
Vilnius, V. Nagevičiaus g. 3, LT-08237
Registration date
2023-04-04
Company age: 3 y. 6 mo.
Contact information
Edit data
Phone
Presented as an image – cannot be copied
Email
Presented as an image – cannot be copied
Website
None
Indicators
Risk factors
Activity
Legal form
Public Institution
NACE activity
Other education n.e.c.
Sector
Namų ūkiams paslaugas teikiančios ne pelno institucijos
Ownership form
Private without foreign capital
Beneficiary of support
Yes, since 2023-05-18
NVO
Non-governmental organization since 2024-12-05
VšĮ OncoAlert 360
Company code: 306289333
Address: Vilnius, V. Nagevičiaus g. 3, LT-08237
Description
This description was generated by artificial intelligence.
OncoAlert 360, VšI (company code 306289333) is an operational Public Institution registered on 2023-04-04. It is classified as a public entity in the non-profit institutions providing services to households sector and is described as privately owned, with Lithuanian natural and legal persons holding more than 50% of the authorised capital and no foreign investor capital. Governance is listed as CEO only, and the company is classified as micro-sized. The company operates from Vilnius, V. Nageviciaus g. 3, LT-08237, in Vilnius city municipality, Vilnius county. Its main activity is under EVRK code Q.85.59.00, Other education n.e.c. Financially, the company reported revenue of €77.9K and net profit of €24.1K in 2023 over a 166-day period, with a profit margin of 30.9%. In 2024, revenue was €26.3K and net profit €3.1K, with a profit margin of 11.8%. Equity increased from €24.1K in 2023 to €27.2K in 2024, while total assets reached €56.4K and liabilities were €1.2K at the end of 2024. No employee figures are provided in the supplied data, and the latest staff year is 2026 so far.
Download a detailed company report
Make confident decisions with all the information about OncoAlert 360, VšĮ. In one document, you will find full financial data, risk and potential assessment, and key Scoris insights.